Patheon buying rival Puerto Rican drug maker
Article Abstract:
Contract drug maker Patheon Inc., is buying rival MOVA Pharmaceuticals Corp. of Puerto Rico for $316-million. The acquisition represents a strategy shift for Mississauga-based Patheon, which has historically purchased excess manufacturing plants from pharmaceutical firms, with contracts in place to continue making the plant's products.
Publication Name: Globe & Mail (Toronto, Canada)
Subject: News, opinion and commentary
ISSN: 0319-0714
Year: 2004
User Contributions:
Comment about this article or add new information about this topic:
Drug maker Patheon blazes trail
Article Abstract:
Mississauga, Ont.-based Patheon Inc., which is a contract drug manufacturer, is a major supplier of key drugs to the world's top pharmaceutical companies. Patheon reported $418 million in total revenues last year.
Publication Name: Globe & Mail (Toronto, Canada)
Subject: News, opinion and commentary
ISSN: 0319-0714
Year: 2003
User Contributions:
Comment about this article or add new information about this topic:
Drug firm Patheon 'disappointed' by third quarter
Article Abstract:
The details on Patheon Inc., which posted a decline in profits for fiscal third quarter, are presented.
Publication Name: Globe & Mail (Toronto, Canada)
Subject: News, opinion and commentary
ISSN: 0319-0714
Year: 2005
User Contributions:
Comment about this article or add new information about this topic:
- Abstracts: Mining stocks, metal prices rise. Iamgold climbs on proposed deal with Gold Fields. Luscar units leap after offer
- Abstracts: Defending Canada's biggest bank machine. Driving a red sports car into bankers' heaven. A man with emotion at the Royal Bank
- Abstracts: T-Mobile USA to start selling new version of BlackBerry. Vancouver firm 'exicted' about sale
- Abstracts: TD takes aim at rivals with major boost to brokerages. Nixon assails insurance rules. Put no limit on mergers or ban all: TD boss
- Abstracts: Independence makes big gains in the boardroom. Changes ease investors' liability fears. Thiessen seeks U.S. audit rules exemption